Antiemetic Medications for Cancer Treatment

Introduction to Antiemetic Regimens

The National Comprehensive Cancer Network recommends that antiemetic medications be administered prophylactically before chemotherapy based on the emetogenic potential of the chemotherapy regimen to prevent nausea and vomiting in patients undergoing cancer treatment 1, 2

For high emetogenic risk chemotherapy, a three-drug combination is recommended, including an NK1 receptor antagonist, a 5-HT3 antagonist, and dexamethasone, according to the National Comprehensive Cancer Network 1, 2, 3
For moderate emetogenic risk chemotherapy, a two-drug combination is recommended, including a 5-HT3 antagonist and dexamethasone, as suggested by the National Comprehensive Cancer Network 3, 4, 5
For low emetogenic risk chemotherapy, a single agent, such as dexamethasone, metoclopramide, or prochlorperazine, is recommended, according to the National Comprehensive Cancer Network 3, 4

The National Comprehensive Cancer Network recommends the administration of granulocyte colony-stimulating factor (G-CSF) prophylactically before or after chemotherapy to reduce the risk of febrile neutropenia and related complications in patients undergoing cancer treatment 6

For patients receiving taxanes, platinum compounds, or monoclonal antibodies, premedications, such as dexamethasone, H1 antagonists, and H2 antagonists, are recommended to prevent hypersensitivity reactions, as suggested by the National Comprehensive Cancer Network 5, 7

The National Comprehensive Cancer Network recommends that antiemetic medications can be safely administered to patients with HIV receiving cancer treatment, and that antiretroviral therapy should be continued during cancer treatment 6
The National Comprehensive Cancer Network also suggests limiting prolonged steroid use for antiemetic therapy to reduce the risk of opportunistic infections in patients with HIV 3, 6

For breakthrough symptoms, adding olanzapine or an agent from a different class, such as lorazepam, dopamine antagonist, or cannabinoid, is recommended, as suggested by the National Comprehensive Cancer Network 2, 3, 4
For anticipatory nausea/vomiting, lorazepam and behavioral modification techniques are recommended, according to the National Comprehensive Cancer Network 3, 4, 5

Antiemetic regimens should be chosen based on the drug with the highest emetic risk in the chemotherapy regimen, and protection must cover the entire period of risk, as recommended by the National Comprehensive Cancer Network 1, 8
Oral and IV antiemetic formulations have equivalent efficacy, and palonosetron is preferred among 5-HT3 antagonists for highly emetogenic chemotherapy due to its longer half-life, according to the National Comprehensive Cancer Network 3, 9